Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Cappuzzo · SciRah

Researcher profile · Semantic Scholar

F. Cappuzzo

Share profile

F. Cappuzzo — researcher profile on SciRah

h-index: 85
Works: 559
Citations: 45K

Most-cited papers

Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
N. Normanno, A. Morabito, A. Rachiglio, Vincenzo Sforza +5 more
2025Nature Reviews Clinical Oncology64 citations
Semantic Scholar
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
P. Marchetti, G. Curigliano, M. Biffoni, S. Lonardi +63 more
2025Nature Medicine43 citations Open access
Semantic Scholar
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
B. Ricciuti, Francesca Fusco, Alissa J. Cooper, E. Garbo +24 more
2025JAMA Oncology42 citations Open access
Semantic Scholar
Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer
F. di Modugno, A. Di Carlo, Sheila Spada, B. Palermo +27 more
2024EBioMedicine36 citations Open access
Semantic Scholar
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study
C. Catania, S.-V. Liu, M. Garassino, A. Delmonte +18 more
2025ESMO Open22 citations Open access
Semantic Scholar
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
A. Di Federico, Kai-Wen Wang, Monica F. Chen, A. Barsouk +42 more
2025The Lancet Oncology19 citations
Semantic Scholar
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC
F. Cappuzzo, Z. Zvirbule, E. Korbenfeld, J. Kolb-Sielecki +9 more
2025JTO Clinical and Research Reports15 citations Open access
Semantic Scholar
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.
F. Gallina, D. Marinelli, Riccardo Tajè, P. Visca +13 more
2025European Journal of Cancer10 citations
Semantic Scholar
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study.
M. Reck, J. Patel, J. Gray, N. Reguart +13 more
2025Journal of Thoracic Oncology10 citations Open access
Semantic Scholar
Global advances and future directions in lung cancer care: expert consensus and strategic priorities
May-Lucie Meyer, S. Peters, P. Jänne, Tony S. K. Mok +55 more
2026ESMO Open9 citations Open access
Semantic Scholar
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer
B. Ricciuti, S. Scalera, X. Wang, A. Elkrief +23 more
2025Annals of Oncology9 citations Open access
Semantic Scholar
Rediscovering immunohistochemistry in lung cancer.
A. La Salvia, May-Lucie Meyer, Fred R. Hirsch, K. Kerr +3 more
2024Critical reviews in oncology/hematology9 citations
Semantic Scholar
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
A. Botticelli, C. Cremolini, S. Scagnoli, M. Biffoni +42 more
2025Clinical Cancer Research8 citations Open access
Semantic Scholar
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
Mark A. Socinski, R. Stahel, Dae Ho Lee, F. Cappuzzo +17 more
2026JAMA Oncology6 citations Open access
Semantic Scholar
Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review
A. Torchia, G. Ciappina, Maristella Giammaruco, I. Monteferrante +2 more
2025Biologics : Targets & Therapy6 citations Open access
Semantic Scholar
Spatial transcriptomics highlights B cells as key contributors to a complete and durable response to chemo-immunotherapy in a patient with resectable NSCLC
Nicla Porciello, F. Gallina, G. Frisullo, Francesca Fusco +7 more
2025Journal for ImmunoTherapy of Cancer6 citations Open access
Semantic Scholar
A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy
F. Musicco, Chiara Fulgenzio, Antonia Marina La Malfa, Nicoletta Jannitti +12 more
2024Journal of Oncology Pharmacy Practice6 citations Open access
Semantic Scholar
MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial.
F. Cappuzzo, B. Ricciuti, A. Delmonte, L. Bonanno +20 more
2025Clinical Cancer Research5 citations
Semantic Scholar
Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study
L. Pusztai, V. Sondak, R. Aguiar-Ibáñez, F. Cappuzzo +19 more
2025Journal for ImmunoTherapy of Cancer5 citations Open access
Semantic Scholar
Molecular characterization of early-stage lung adenocarcinoma presenting as subsolid nodules in a real-life European cohort
Riccardo Tajè, F. Gallina, Mauro Caterino, D. Forcella +11 more
2025BMC Cancer5 citations Open access
Semantic Scholar
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
Tian-Shi Lu, H. Hamidi, Mark A. Socinski, M. Reck +16 more
2025Nature Communications5 citations Open access
Semantic Scholar
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
S. Peters, C. Schulz, Martin Reck, K. Prabhash +23 more
2025Journal of Thoracic Oncology4 citations
Semantic Scholar
Supraclavicular Lymph Node Metastases in Advanced Lung Cancer: Prevalence and Analysis of Demographic, Clinical and Molecular Characteristics.
R. Trisolini, V. Cetoretta, G. Sotgiu, A. Cancellieri +8 more
2025Clinical Lung Cancer4 citations Open access
Semantic Scholar
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study
E. Adib, A. H. Nassar, Katie N Lee, Francesca Fusco +25 more
2025JTO Clinical and Research Reports4 citations Open access
Semantic Scholar
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.
J. Gray, Joel W. Neal, J. Patel, Stephen V. Liu +13 more
2026Clinical Cancer Research3 citations
Semantic Scholar
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.
A. Di Federico, S. Compagno, F. Mantuano, S. Stumpo +15 more
2026JAMA Oncology3 citations Open access
Semantic Scholar
ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors.
S.-V. Liu, R. Dziadziuszko, S. Viteri, F. Cappuzzo +8 more
2025Lung Cancer3 citations
Semantic Scholar
Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy.
Stephen V. Liu, C. Guibert, Elvire Pons Tostivint, R. Califano +13 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.
D. Marinelli, F. Citarella, A. Torchia, Sagal Pannu +25 more
2026Cancer Treatment Reviews2 citations Open access
Semantic Scholar
The role of the molecular tumor board: learnings from the ROME trial
P. Marchetti, G. Curigliano, C. B. Westphalen, M. Biffoni +65 more
2026npj Precision Oncology2 citations Open access
Semantic Scholar
NSCLC in Vulnerable and Special Populations: Toward Personalized Care.
Claudia Parisi, A. De Giglio, Marco Banini, M. Tagliamento +11 more
2026Journal of Thoracic Oncology2 citations
Semantic Scholar
Telisotuzumab adizutecan (Temab-A) plus osimertinib (osi) as 1L treatment for unresectable/metastatic NSCLC.
Y. Goto, C. Baik, F. Cappuzzo, D. Camidge +13 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
Mauricio Burotto, Z. Zvirbule, Renzo Alvarez, B. Chewaskulyong +12 more
2026Lung Cancer2 citations Open access
Semantic Scholar
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials.
A. Torchia, A. Sabatini, E. Bengala, Mattia Alberto Di Civita +9 more
2025Lung Cancer2 citations Open access
Semantic Scholar
233P: Chemo-immunotherapy for borderline resectable and unresectable NSCLC
F. Cappuzzo, L. Landi, E. Garbo, A. Cooper +16 more
2025Journal of Thoracic Oncology2 citations
Semantic Scholar
Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial
L. Landi, R. Chiari, M. Tiseo, G. Metro +15 more
2025JTO Clinical and Research Reports2 citations Open access
Semantic Scholar
The Effects of Race on Anti-PD-(L)1 Monoclonal Antibodies in Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis.
C. Genova, F. Cappuzzo, Giorgio Minotti, N. Normanno +4 more
2025Critical reviews in oncology/hematology2 citations Open access
Semantic Scholar
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
May-Lucie Meyer, Solange Peters, Hossein Borghaei, T. Cascone +86 more
2026Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.
L. Cipriani, Davide Mascolo, S. Scalera, Giulia Bon +24 more
2026Clinical Cancer Research1 citations
Semantic Scholar
A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)
A. Navarro, A. Thomas, Y. Cheng, Y. Chen +15 more
2025ESMO Open1 citations
Semantic Scholar
Short term outcomes of robotic surgery after neoadjuvant treatment for locally advanced NSCLC: a comparison with the open approach
F. Gallina, Riccardo Tajè, D. Forcella, Gabriele Alessandrini +5 more
2025Frontiers in Oncology1 citations Open access
Semantic Scholar
Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung Adenocarcinoma.
Riccardo Tajè, Vincenzo Ambrogi, F. Tacconi, F. Gallina +13 more
2025Clinical Lung Cancer1 citations
Semantic Scholar
DESTINY of Immunotherapy in Patients With HER2 Mutant Lung Cancer: Case Report
L. Landi, Francesca Fusco, E. Melis, S. Buglioni +3 more
2025JTO Clinical and Research Reports1 citations
Semantic Scholar
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer
M. Majem, B. Chewaskulyong, Z. Zvirbule, Ki Hyeong Lee +8 more
2025Oncology and Therapy1 citations
Semantic Scholar
Erratum to 'Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100815].
F. Cappuzzo, Z. Zvirbule, E. Korbenfeld, J. Kolb-Sielecki +9 more
2025JTO Clinical and Research Reports1 citations Open access
Semantic Scholar
Abstract 7753: Circulating thymidine kinase activity (TKa) as a predictive and dynamic biomarker in the metastatic non-small cell lung cancer (NSCLC): Immunoblood study
Maristella Giammaruco, L. Landi, M. Bergqvist, G. Minuti +12 more
2026Cancer Research0 citations
Semantic Scholar
Abstract PR005: KRAS amplification as de novo oncogenic alteration and therapeutic target in human cancers
Mark M. Awad, B. Ricciuti, S. V. Michelina, E. Garbo +31 more
2026Cancer Research0 citations
Semantic Scholar
PP01.47: PD-(L)1 Inhibitor Monotherapy Versus Chemo-Immunotherapy for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and PD-L1 Expression ≥50%: A Systematic Review and Meta-Analysis with Individual Patient Data
Alessandro Di Federico, S. Compagno, F. Mantuano, S. Stumpo +15 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
256P Impact of surgical extent on recurrence-free survival in STAS-positive non-small cell lung cancer: A reconstructed IPD meta-analysis
F. Gallina, R. Taje', G. Alessandrini, D. Forcella +6 more
2026ESMO Open0 citations Open access
Semantic Scholar
150TiP A phase Ib/II trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with anticancer agents in first-line (1L) for advanced solid tumors (Symbiotic-Lung-20)
E. Felip, F. Cappuzzo, R. Martins, B. Wang +11 more
2026ESMO Open0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Landi×12
Invite
L. Landi — researcher profile on SciRah
B. Ricciuti×9
Invite
B. Ricciuti — researcher profile on SciRah
Francesca Fusco×9
Invite
Francesca Fusco — researcher profile on SciRah
F. Gallina×7
Invite
F. Gallina — researcher profile on SciRah

×7

Invite

S. Buglioni — researcher profile on SciRah

Invite

P. Visca — researcher profile on SciRah

A. Di Federico×6

Invite

A. Di Federico — researcher profile on SciRah

Invite

B. Besse — researcher profile on SciRah

Invite

G. Metro — researcher profile on SciRah

Federica Pecci×5

Invite

Federica Pecci — researcher profile on SciRah

Invite

Xinan Wang — researcher profile on SciRah

Invite

E. Melis — researcher profile on SciRah